Young Pharmaceuticals Partners with LAC2βiome to Launch Microbiome-Based Skincare Line

The first product to enter the market out of the Young Pharmaceuticals and LAC2βiome skin care line is the BiomeAge, a combination of hyaluronic acid with live Lactobacillia packaged in a patented mixing ampoule.
The first product to enter the market out of the Young Pharmaceuticals and LAC2βiome skin care line is the BiomeAge, a combination of hyaluronic acid with live Lactobacillia packaged in a patented mixing ampoule.
Courtesy of Young Pharmaceuticals

Young Pharmaceuticals, Inc., a physician-dispensed skin care provider, has announced its product line with LAC2βiome S.r.l., a manufacturer of microbial based products, according to a Jan. 14 announcement.

The InfiniteSkin Microbiome products, born from Young’s collaboration with LAC2βiome S.r.l., deliver live beneficial bacteria to the skin. 

The first product to enter the market out of this skin care line is the BiomeAge, a combination of hyaluronic acid with live Lactobacilli packaged in a patented mixing ampoule. 

The BiomeAge line will only be available through dispensing medical offices and their online stores. 

“We are pleased to partner with Young as we share a similar focus on science-driven product development and overall excitement for microbial based skin care solutions," says Lasse Nagell, LAC2βiome CEO and Co-Founder.

Footnote:

aLactobacilli: bacteria that supports a balanced microbiome by promoting the growth of good bacteria.

More in Events